胃癌治療市場規模、佔有率和成長分析：按治療類型、分期、最終用戶、通路和地區分類－2026-2033年產業預測

2024 年全球胃癌治療市場價值為 35.2 億美元，預計到 2025 年將成長至 38.3 億美元，到 2033 年將成長至 75.2 億美元，在預測期（2026-2033 年）內複合年成長率為 8.82%。

全球胃癌治療市場正因胃癌發病率的不斷上升和相關未滿足需求的持續存在而重塑，這對全球發病率和死亡率產生了顯著影響。手術介入、全身性治療、標靶治療、免疫療法和支持性護理在各個治療階段都發揮著至關重要的作用。該市場尤其集中在東亞地區，老齡化人口推動了各國篩檢力度的加強和私人投資的增加。從傳統的切除術和化療轉向基於生物標記的治療，凸顯了基因組檢測的重要性，並使曲妥珠單抗和查核點抑制劑等標靶治療得以應用。中國和東南亞等地區保險報銷政策的改善、癌症治療基礎設施的擴建以及人口結構的變化，進一步刺激了市場需求，促進了診斷和治療領域的合作，並最終推動了收入成長。

全球胃癌治療市場成長要素

全球胃癌治療市場的發展主要得益於分子診斷和標靶治療的不斷進步。這些技術使醫療專業人員能夠精準地對腫瘤亞型進行分類，並最佳化治療方案，從而提高療效和個人化治療水平。癌症治療中心擴大採用創新藥物和聯合治療，不僅增強了醫生製定強化治療方案的信心，也刺激了研發投入。隨著臨床決策日趨複雜，藥廠和醫療機構將更重視與分子譜分析相契合的治療方法。這將有助於人們更充分地認知到治療的價值，改善患者預後，並最終推動市場擴張。

全球胃癌治療市場阻礙因素

全球胃癌治療市場面臨許多挑戰，其中創新治療方法和複雜治療方法的高昂成本尤其突出。這些成本給患者和醫療系統都帶來了沉重的經濟負擔，可能阻礙患者充分受益於這些先進療法的臨床療效。此外，保險報銷政策的限制以及不同地區醫保覆蓋範圍的差異也限制了醫療服務提供者開立這些高成本藥物的能力。因此，製藥公司在取得健保覆蓋方面面臨許多困難。預算緊張的醫療機構可能會選擇成熟的、成本較低的替代療法，導致新治療方法的推廣應用被延緩。

全球胃癌治療市場趨勢

全球胃癌治療市場正經歷著向「精準腫瘤學」的重大轉變，分子譜分析和基於生物標記的治療方法的整合正在革新患者照護。這項轉變使臨床醫生能夠根據腫瘤獨特的生物學特徵制定個人化治療方案，從而最大限度地降低患者接受無效藥物的風險。診斷測試開發商和製藥公司之間的合作正在為未來更豐富的標靶治療和伴隨診斷鋪平道路。隨著多學科團隊擴大在臨床決策中利用基因組數據，這一趨勢強調了個人化治療方法，刺激了轉化研究的投資，並透過根據每位患者的個別生物學特徵量身定做治療策略來提升治療價值。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球胃癌治療市場規模：依治療類型分類

• 化療
• 標靶治療
  • HER2抑制劑（曲妥珠單抗）
  • VEGF抑制劑（Ramucirumab單抗）
• 免疫療法（Nivolumab，Pembrolizumab）
• 外科手術
• 放射線治療

全球胃癌治療市場規模：依階段分類

• 早期的
• 晚期，轉移性

全球胃癌治療市場規模：依最終用戶分類

• 醫院
• 癌症中心

全球胃癌治療市場規模：依通路分類

• 醫院藥房
• 專科藥房

全球胃癌治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Roche（Herceptin/Trastuzumab）
• Eli Lilly（Cyramza/Ramucirumab）
• Bristol Myers Squibb（Opdivo）
• Merck & Co.（Keytruda）
• AstraZeneca（Enhertu-co-marketed）
• Daiichi Sankyo（Enhertu）
• Zymeworks
• Seagen Inc.
• Zanosar（Pfizer）
• Taiho Pharmaceutical
• Ono Pharmaceutical
• Taisho Pharmaceutical
• Hikma Pharmaceuticals
• Akeso Inc.
• Innovent Biologics
• BeiGene Ltd.
• ZymeBio
• Corvus Pharmaceuticals
• Mirati Therapeutics
• MacroGenics Inc.

結論與建議

Global Stomach Cancer Treatment Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 3.83 Billion in 2025 to USD 7.52 Billion by 2033, growing at a CAGR of 8.82% during the forecast period (2026-2033).

The global stomach cancer treatment market is being reshaped by the increasing incidence and unmet clinical needs associated with the disease, which significantly impacts global morbidity and mortality. Surgical interventions, systemic therapies, targeted agents, immunotherapies, and supportive care play vital roles throughout various treatment phases. The market is particularly concentrated in East Asia, affecting aging populations, leading to national screening initiatives and heightened private investment. The evolution from traditional gastrectomy and chemotherapy to biomarker-driven therapies highlights the significance of genomic testing, allowing for targeted interventions like trastuzumab and checkpoint inhibitors. Enhanced reimbursement policies, growing oncology infrastructure, and demographic shifts in regions like China and Southeast Asia further stimulate demand while encouraging partnerships for diagnostics and therapeutics, ultimately driving revenue growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Stomach Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Stomach Cancer Treatment Market Segments Analysis

Global stomach cancer treatment market is segmented by treatment type, stage, end-user, distribution and region. Based on treatment type, the market is segmented into chemotherapy, targeted therapy, immunotherapy (nivolumab, pembrolizumab), surgery and radiation therapy. Based on stage, the market is segmented into early stage and advanced/metastatic. Based on end-user, the market is segmented into hospitals and cancer centers. Based on distribution, the market is segmented into hospital pharmacies and specialty pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Stomach Cancer Treatment Market

The Global Stomach Cancer Treatment market is driven by ongoing advancements in molecular diagnostics and targeted therapies, enabling healthcare professionals to accurately classify tumor sub-types and tailor treatment approaches for enhanced effectiveness and personalization. This growing adoption of innovative agents and combination therapies in oncology centers not only boosts physician confidence in prescribing intensive treatments but also stimulates investments in research and development. As clinical decision-making becomes more refined, manufacturers and providers are likely to focus on therapies that align with molecular profiling, thereby elevating the perceived value of treatments and improving patient outcomes, which ultimately expands the market.

Restraints in the Global Stomach Cancer Treatment Market

The Global Stomach Cancer Treatment market faces notable challenges due to the high costs associated with innovative therapies and complex treatment regimens. These expenses present significant financial burdens for both patients and healthcare systems, potentially hindering access to the full clinical benefits of these advanced treatments. Additionally, limited reimbursement policies and inconsistent coverage across different regions restrict healthcare providers' capacity to prescribe these high-cost agents. As a result, manufacturers encounter difficulties in achieving formulary placement. Institutions with budget constraints may opt for established, lower-cost alternatives, leading to delays in the adoption of newer treatment options.

Market Trends of the Global Stomach Cancer Treatment Market

The Global Stomach Cancer Treatment market is witnessing a significant trend towards precision oncology, where the integration of molecular profiling and biomarker-driven therapies is revolutionizing patient care. This shift enables clinicians to tailor treatments based on the unique biology of tumors, minimizing patients' exposure to ineffective drugs. Collaborative efforts between diagnostic test developers and pharmaceutical companies are setting the stage for a future rich in targeted therapies and companion diagnostics. As multidisciplinary teams increasingly utilize genomic data in clinical decision-making, the trend emphasizes personalized treatment approaches, stimulates investment in translational research, and enhances the therapeutic value by aligning treatment strategies with specific patient biology.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Stomach Cancer Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Targeted Therapy
  • HER2 Inhibitors (Trastuzumab)
  • VEGF Inhibitors (Ramucirumab)
• Immunotherapy (Nivolumab, Pembrolizumab)
• Surgery
• Radiation Therapy

Global Stomach Cancer Treatment Market Size by Stage & CAGR (2026-2033)

• Market Overview
• Early Stage
• Advanced/Metastatic

Global Stomach Cancer Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Centers

Global Stomach Cancer Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Stomach Cancer Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Stage, End-User, Distribution)
  • US
  • Canada
• Europe (Treatment Type, Stage, End-User, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Stage, End-User, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Stage, End-User, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Stage, End-User, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche (Herceptin/Trastuzumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Cyramza/Ramucirumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Opdivo)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (Keytruda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (Enhertu - co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Enhertu)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seagen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zanosar (Pfizer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taiho Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taisho Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akeso Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ZymeBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corvus Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mirati Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations